Eton Pharmaceuticals Inc Market Cap ($1.45 Billion)
Market Cap & Net Worth: Eton Pharmaceuticals Inc (ETON)
Eton Pharmaceuticals Inc market cap. Eton Pharmaceuticals Inc (NASDAQ:ETON) has a market capitalization of $1.45 Billion ($1.45 Billion) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7127 globally and #2202 in its home market, demonstrating a -0.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eton Pharmaceuticals Inc's stock price $50.72 by its total outstanding shares 28583135 (28.58 Million). Also see cash flow conversion of Eton Pharmaceuticals Inc for how efficiently the company converts equity into cash flow.
Eton Pharmaceuticals Inc Market Cap History (2018–2026)
Eton Pharmaceuticals Inc market cap history from 2018 to 2026. Data shows growth from $174.93 Million to $1.45 Billion (30.00% CAGR). Check ETON stock price for real-time trading data and today's change.
Index Memberships
Eton Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.06% | #205 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #797 of 3165 |
Weight: Eton Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Eton Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eton Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Eton Pharmaceuticals Inc (ETON) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6.05x
Eton Pharmaceuticals Inc's market cap is 6.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $205.80 Million | $959.00K | -$18.32 Million | 214.60x | N/A |
| 2020 | $232.38 Million | $39.00K | -$27.97 Million | 5958.48x | N/A |
| 2021 | $122.62 Million | $21.83 Million | -$1.96 Million | 5.62x | N/A |
| 2022 | $80.60 Million | $21.25 Million | -$9.02 Million | 3.79x | N/A |
| 2023 | $125.19 Million | $31.64 Million | -$936.00K | 3.96x | N/A |
| 2024 | $380.73 Million | $39.01 Million | -$3.82 Million | 9.76x | N/A |
| 2025 | $483.34 Million | $79.95 Million | -$4.60 Million | 6.05x | N/A |
Competitor Companies of ETON by Market Capitalization
Companies near Eton Pharmaceuticals Inc in the global market cap rankings as of November 5, 2026. Also see ETON asset base for a full breakdown of the balance sheet.
Key companies related to Eton Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Eton Pharmaceuticals Inc (2018–2026)
Market capitalization of Eton Pharmaceuticals Inc from 2018 to today. Between 2018 and today, Eton Pharmaceuticals Inc's market cap moved from $174.93 Million to $ 1.45 Billion, with a yearly change of 30.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.45 Billion | +199.94% |
| 2025 | $483.34 Million | +26.95% |
| 2024 | $380.73 Million | +204.11% |
| 2023 | $125.19 Million | +55.32% |
| 2022 | $80.60 Million | -34.27% |
| 2021 | $122.62 Million | -47.23% |
| 2020 | $232.38 Million | +12.92% |
| 2019 | $205.80 Million | +17.65% |
| 2018 | $174.93 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Eton Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.45 Billion USD |
| MoneyControl | $1.45 Billion USD |
| MarketWatch | $1.45 Billion USD |
| marketcap.company | $1.45 Billion USD |
| Reuters | $1.45 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for … Read more